The prognostic significance of the omental chemotherapy response score in hereditary ovarian tumors after neoadjuvant chemotherapy
Abstract
The study was aimed to evaluate histopathological tumor response of omental metastases in BRCA1-associated and sporadic ovarian tumors after platinum-based neoadjuvant chemotherapy (NACT). We selected patients with histologically confirmed ovarian high-grade serous carcinoma who were treated with NACT followed by optimal debulking. Forty patients (14 BRCA1-associated cancers and 26 sporadic cases) meeting the criteria mentioned above were enrolled in the pathological examination. Clinical data (platinum-free interval, PFI) were collected through database review. Good regress [score 3] was observed in 4 out of 16 (25%) BRCA1-associated carcinomas and in one of 24 (4%) sporadic cancers (p = 0.14, Fisher's exact test). PFI was associated with the degree of response (minimal regress - median PFI 3.62 months, moderate regress - median 8.17 months, good regress - 21.28 months, p = 0.026, Kruskal-Wallis test). The omental response score predicted platinum-free interval in BRCA1-associated tumors (score 2+3 vs. 1; median PFI, 18.6 vs. 2.9 months; p = 0.04, Mann-Whitney U test). Histopathological tumor response of omental metastasis in BRCA1-associated and sporadic ovarian tumors after platinum-based neoadjuvant chemotherapy predicts PFI.
About the Authors
A. O. Ivantsov
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
M. A. Kleshchov
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
T. V. Gorodnova
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
K. B. Kotiv
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
E. N. Imyanitov
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
A. P. Sokolenko
ФГБУ «НМИЦ онкологии им. Н.Н. Петрова» Минздрава России
Russian Federation
Russian Federation
References
1. Tropé C.G., Elstrand M.B., Sandstad B., et al. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?, Eur. J. Cancer 48 (14) (2012) 2146-2154.
2. Böhm S., Faruqi A., Said I., et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol. 2015 Aug 1;33(22):2457-63.
3. Lee J.Y., Chung Y.S., Na K., et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol. 2017 Nov;28(6):e73.
4. Tan D.S., Rothermundt C., Thomas K. et al. «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome ofpatients with epithelial ovarian cancer associated with BRCA1 and BRCA2 // J. Clin. Oncol. 2008. Vol. 26 (34). P. 5530-5536.
5. Petrillo M., Zannoni G.F., Tortorella L., et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. AM J Obstet Gynecol. 2014; 211: 632. e1-8.
6. Sokolenko A.P., Savonevich E.L., Ivantsov A.O., et al. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. Cancer Lett. 2017 Jul 1;397:127-132.
7. Said I., Böhm S., Beasley J., et al. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. Int J Gynecol Pathol. 2017; 36(2):172-179.
8. Gorodnova T.V., Sokolenko A.P., Ivantsov A.O., et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Lett. 2015; 369(2):363-7.
9. Ledermann J.A., Raja F.A., Fotopoulou C., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32.
10. Sassen S., Schmalfeldt B., Avril N., et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38:926-934.
Review
For citations:
Ivantsov AO, Kleshchov MA, Gorodnova TV, Kotiv KB, Imyanitov EN, Sokolenko AP. The prognostic significance of the omental chemotherapy response score in hereditary ovarian tumors after neoadjuvant chemotherapy. Ural Medical Journal. 2018;(2):39-42. (In Russ.)
Views:
159
Email this article 